Amneal Pharmaceuticals (AMRX) and Fresenius Kabi's mAbxience unit said Monday that the US Food and Drug Administration accepted for review their biologics licensing application for two proposed denosumab biosimilars.
Denosumab is a monoclonal antibody that inhibits bone resorption and is used to treat conditions such as osteoporosis and bone metastases from cancer.
The US regulator has set a target action date in Q4, according to the companies.
Amneal has exclusive commercialization rights for the biosimilars in the US, while mAbxience is responsible for development and manufacturing, they added.
Amneal currently markets three biosimilars in the US and aims to expand its portfolio to six biosimilars across eight product presentations by 2027.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。